Exalpha Biologicals, Inc.

Accelerating the Pace of Discovery

Product Highlight

Mouse anti-M13 phage coat protein g8p

Antibodies recognising M13 filamentous phage coat proteins are instrumental in the selection and detection of phages expressing specific antibody fragments or peptide sequences at their surface. The monoclonal antibodies manufactured and supplied by Exalpha react with either the pIII (g3p) or pVIII (g8p) proteins of M13 filamentous bacteriophage. All antibodies are available in a purified format. The antibodies are fully validated and are suitable for a wide range of techniques including:

  • Flow Cytometry
  • Western Blot
  • Immunohistochemistry
  • Immunoprecipitation
For more information, click here for our M13 Bacteriophage information page.


Two more of our excellent products have been published by PubMed:

Potential actionable targets in appendiceal cancer detected by immunohistochemistry, fluorescent in situ hybridization, and mutational analysis
Borazanci, E., et al., J. Gastrointest. Oncol., 8, 164-172 (2017)
Using Exalpha SPARC Antibody (Cat. No. X1867P)

Molecular mechanism underlying the pharmacological interactions of the protein kinase C-β inhibitor enzastaurin and erlotinib in non-small cell lung cancer cells
Steen, N.V., et al., Am. J. Cancer Res., 7, 816-830 (2017)
Using Exalpha's FITC labeled anti PY20 Antibody (Cat. No. X1017)

Exalpha Biologicals, Inc.

PTPbeta (1675-1996) N Terminal GST Tag

  • Product Code: X1665E
  • Size: 20 µg
  • Price (USD): $361

Cat #

X1665E		 Quantity:      

Data Sheet

Product Name

PTPbeta (1675-1996) N Terminal GST Tag



Product Type

Active Enzyme




Useful for the study of enzyme kinetics, screening inhibitors, and selectivity profiling.


20 µg

Price (USD)



PTP beta, also known as Receptor-type tyrosine-protein phosphatase beta [Precursor], Protein-tyrosine phosphatase beta,R-PTP-beta, PTPRB or PTPB is a protein tyrosine phosphatase and is overexpressed in glioblastoma tumors. PTP beta plays a n important functional role in tumor cell migration and adhesion. Glioblastomas express at least three splice variants of PTPbeta, including long and short receptor forms. The short form of PTPbeta lacks exon 12, which encodes 860 amino acids located in the extracellular domain. In normal brain tissue and graded astrocytomas the long and short PTPbeta forms have an overlapping expression pattern. U87 stable cell lines overexpressing long or short PTPbeta migrate faster and adhere more robustly than parental U87 cells. The involvement of long and short PTPbeta in glioma tumor cell biology also contributes to the value of PTPbeta as a cancer target.


Recombinant enyzme produced in E. coli


Provided in 25 mM Tris-HCl, 75 mM NaCl, pH 8.0, 0.05% Tween, 5 mM DTT and 50% glycerol

Customer Storage

Enzyme should be stored at -20°C. Enzyme should be kept on ice when dispensing

Target Molecular Weight

63.7 kDa

Database Links:



[1] Krueger N.X., Streuli M., Saito H.; Structural diversity and evolution of human receptor-like protein tyrosine phosphatases.; EMBO J. 9:3241-3252(1990).

[2] Brunner RM, Rottengatter K, Horstmann RD, Gelhaus A, Goldammer T, Foerster B, Schwerin M.
Assignment of the protein-tyrosine phosphatase beta gene (PTPRB) to cattle chromosome 5q23q24 by in situ hybridization and somatic cell panel analysis.
Cytogenet Genome Res. 2003;103(1-2):203G.

[3] Cheburkin IuV, Kniazeva TG, Peter S, Kniazev IuP, Karelin MI, Shkol'nik MI, Evtushenko VI, Hanson KP, Ullrich A, Kniazev PG. [Molecular portrait of human kidney carcinomas: the gene expression profiling of protein-tyrosine kinases and tyrosine phosphatases which controlled regulatory signals in the cells] Mol Biol (Mosk). 2002 May-Jun;36(3):480-90. Russian.

[4] Harder KW, Anderson LL, Duncan AM, Jirik FR. The gene for receptor-like protein tyrosine phosphatase (PTPRB) is assigned to chromosome 12q15-->q21. Cytogenet Cell Genet. 1992;61(4):269-70.

[5] Lorente G, Nelson A, Mueller S, Kuo J, Urfer R, Nikolich K, Foehr ED. Functional comparison of long and short splice forms of RPTPbeta: Implications for glioblastoma treatment. Neuro-oncol. 2005 Apr;7(2):154-63.